Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Sarah Milgrom

Concepts (370)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Hodgkin Disease
41
2026
172
11.840
Why?
Radiotherapy, Intensity-Modulated
17
2026
142
4.070
Why?
Positron Emission Tomography Computed Tomography
17
2026
118
3.770
Why?
Fluorodeoxyglucose F18
8
2026
161
2.300
Why?
Tumor Burden
7
2026
325
2.300
Why?
Radiotherapy
14
2025
206
2.180
Why?
Antineoplastic Combined Chemotherapy Protocols
34
2026
1969
2.150
Why?
Lymphoma
10
2025
241
2.050
Why?
Radiotherapy Planning, Computer-Assisted
15
2026
149
2.050
Why?
Whole-Body Irradiation
3
2026
74
1.880
Why?
Radiation Injuries
9
2025
149
1.870
Why?
Radiotherapy Dosage
18
2026
288
1.690
Why?
Central Nervous System Neoplasms
9
2021
177
1.680
Why?
Radiopharmaceuticals
6
2023
205
1.580
Why?
Hematologic Neoplasms
2
2026
168
1.530
Why?
Lymphoma, Non-Hodgkin
6
2024
124
1.430
Why?
Neoplasm Staging
31
2026
1475
1.390
Why?
Lymphoma, Large B-Cell, Diffuse
8
2024
195
1.260
Why?
Sarcoma
2
2023
207
1.180
Why?
Neoplasm Recurrence, Local
13
2023
1150
1.170
Why?
Salvage Therapy
11
2024
165
1.160
Why?
Neoplasms
8
2026
2913
1.130
Why?
Mediastinal Neoplasms
5
2021
53
1.080
Why?
Endometrial Neoplasms
4
2014
205
1.070
Why?
Prognosis
24
2026
4330
1.050
Why?
Combined Modality Therapy
22
2024
1271
1.030
Why?
Hematopoietic Stem Cell Transplantation
7
2024
699
1.010
Why?
Radiotherapy, Adjuvant
7
2024
222
0.960
Why?
Humans
124
2026
145783
0.950
Why?
Lymphoma, Extranodal NK-T-Cell
1
2026
11
0.940
Why?
Positron-Emission Tomography
9
2025
343
0.920
Why?
Neoplasms, Radiation-Induced
2
2026
100
0.920
Why?
Rhabdomyosarcoma
2
2024
65
0.920
Why?
Neoplasms, Second Primary
2
2026
102
0.890
Why?
Sarcoma, Ewing
2
2024
103
0.880
Why?
Proton Therapy
2
2026
15
0.860
Why?
Disease Progression
7
2024
2865
0.830
Why?
Doxorubicin
14
2026
403
0.810
Why?
Child
29
2026
22740
0.800
Why?
Clinical Trials as Topic
2
2026
1062
0.790
Why?
Radiation
2
2020
24
0.790
Why?
Craniopharyngioma
1
2024
77
0.780
Why?
Young Adult
36
2026
14254
0.780
Why?
Radiation Exposure
1
2023
63
0.760
Why?
Pituitary Neoplasms
1
2024
190
0.740
Why?
Adenocarcinoma
3
2014
926
0.730
Why?
Lymphoma, Follicular
5
2020
56
0.720
Why?
Adolescent
34
2026
22577
0.710
Why?
Salivary Glands
2
2021
36
0.710
Why?
Smiling
1
2021
6
0.710
Why?
Xerostomia
1
2021
13
0.680
Why?
Retrospective Studies
39
2026
17330
0.670
Why?
Tooth Abnormalities
1
2021
16
0.670
Why?
Brachytherapy
1
2021
132
0.640
Why?
Chemoradiotherapy
9
2021
239
0.620
Why?
Face
1
2021
175
0.620
Why?
Cancer Survivors
2
2026
338
0.620
Why?
Bleomycin
9
2025
255
0.620
Why?
Aged, 80 and over
23
2026
8347
0.600
Why?
Vinblastine
9
2025
75
0.600
Why?
Intraocular Lymphoma
2
2016
3
0.600
Why?
Dacarbazine
9
2025
100
0.590
Why?
Aged
43
2026
26217
0.590
Why?
Adult
54
2026
40881
0.580
Why?
Infertility, Female
2
2025
122
0.570
Why?
Middle Aged
51
2026
36309
0.570
Why?
Lymphoma, B-Cell, Marginal Zone
4
2019
19
0.560
Why?
Organs at Risk
4
2026
37
0.560
Why?
Rectal Neoplasms
3
2016
159
0.560
Why?
Female
64
2026
79045
0.550
Why?
Cerebellar Neoplasms
1
2020
177
0.530
Why?
Radiotherapy, Image-Guided
4
2026
40
0.530
Why?
Breast Neoplasms
6
2026
2393
0.530
Why?
Medulloblastoma
1
2020
215
0.520
Why?
Recurrence
9
2020
1139
0.500
Why?
Meningeal Neoplasms
1
2018
95
0.490
Why?
Male
56
2026
73011
0.490
Why?
Leukemia, Biphenotypic, Acute
1
2016
4
0.490
Why?
Leukemia, Myeloid, Acute
2
2023
688
0.480
Why?
Patient Satisfaction
1
2020
712
0.470
Why?
Head and Neck Neoplasms
1
2021
561
0.470
Why?
Treatment Outcome
26
2026
11794
0.450
Why?
Mediastinum
4
2026
23
0.440
Why?
Graft vs Host Disease
2
2024
279
0.440
Why?
Eye Diseases
1
2016
97
0.430
Why?
Brain Neoplasms
3
2023
1331
0.430
Why?
Lower Urinary Tract Symptoms
2
2026
62
0.430
Why?
Follow-Up Studies
16
2025
5428
0.420
Why?
Survival Rate
12
2021
2094
0.420
Why?
Disease-Free Survival
12
2020
770
0.400
Why?
Glycolysis
3
2023
340
0.400
Why?
Endometrium
1
2013
64
0.390
Why?
Peritoneal Cavity
1
2013
30
0.390
Why?
Palate, Hard
1
2012
5
0.380
Why?
Digestive System Surgical Procedures
1
2014
112
0.380
Why?
Lymphoma, B-Cell
3
2021
141
0.370
Why?
Chemoradiotherapy, Adjuvant
3
2019
44
0.370
Why?
Stomach Neoplasms
3
2019
128
0.370
Why?
Mastectomy, Simple
1
2012
1
0.370
Why?
Image Enhancement
1
2013
200
0.360
Why?
Vincristine
5
2026
144
0.350
Why?
Neoadjuvant Therapy
2
2016
467
0.350
Why?
Child, Preschool
9
2026
11868
0.350
Why?
Sentinel Lymph Node Biopsy
1
2012
117
0.340
Why?
Carcinoma, Lobular
1
2012
56
0.340
Why?
Carcinoma, Ductal, Breast
1
2012
90
0.340
Why?
Adrenal Gland Neoplasms
1
2012
98
0.330
Why?
Radiotherapy, Conformal
2
2026
74
0.320
Why?
Cyclophosphamide
4
2026
272
0.320
Why?
Rituximab
4
2026
210
0.310
Why?
Biopsy
6
2020
1082
0.310
Why?
Disease Management
6
2019
653
0.300
Why?
Cellulitis
1
2009
54
0.290
Why?
Tomography, X-Ray Computed
7
2023
2770
0.290
Why?
Antineoplastic Agents
6
2025
2219
0.290
Why?
Carcinoma, Squamous Cell
1
2014
641
0.280
Why?
Prednisone
3
2026
226
0.280
Why?
Kaplan-Meier Estimate
7
2020
971
0.280
Why?
United States
6
2026
16126
0.280
Why?
Lymphocytes
3
2020
376
0.280
Why?
Lymphoma, Mantle-Cell
2
2019
36
0.270
Why?
Organ Sparing Treatments
2
2026
37
0.260
Why?
Coronary Artery Disease
2
2026
750
0.260
Why?
Consensus
3
2024
479
0.250
Why?
Survival Analysis
6
2020
1378
0.240
Why?
Cardiotoxicity
2
2023
35
0.240
Why?
Lung Neoplasms
3
2026
2668
0.240
Why?
Pregnancy Complications, Neoplastic
2
2017
63
0.240
Why?
Ifosfamide
1
2026
39
0.240
Why?
Testicular Neoplasms
2
2018
111
0.240
Why?
Credentialing
1
2026
21
0.230
Why?
Radiation Pneumonitis
2
2016
31
0.230
Why?
Multiple Myeloma
2
2020
309
0.230
Why?
Patient Selection
2
2022
739
0.230
Why?
Pelvic Neoplasms
1
2025
24
0.230
Why?
Heart
3
2018
626
0.220
Why?
Urinary Tract
1
2025
47
0.220
Why?
Urodynamics
1
2025
44
0.220
Why?
Lymph Node Excision
2
2019
173
0.220
Why?
Antimetabolites, Antineoplastic
2
2017
106
0.210
Why?
Risk Factors
6
2026
10919
0.210
Why?
Leukemia
2
2017
246
0.210
Why?
Risk Assessment
6
2023
3752
0.210
Why?
Radiation Oncology
1
2025
82
0.210
Why?
Transplantation, Haploidentical
1
2024
23
0.210
Why?
Central Nervous System
3
2021
282
0.200
Why?
Magnetic Resonance Imaging
4
2019
3916
0.200
Why?
Uterus
1
2025
228
0.200
Why?
Quality Assurance, Health Care
1
2025
342
0.200
Why?
Lymphadenopathy
1
2023
8
0.200
Why?
Virtual Reality
1
2025
82
0.190
Why?
Lymphatic Metastasis
3
2014
336
0.190
Why?
Cord Blood Stem Cell Transplantation
1
2024
103
0.190
Why?
Transplantation Conditioning
1
2024
191
0.190
Why?
Comprehension
1
2025
187
0.190
Why?
Neoplasm Grading
4
2019
311
0.190
Why?
Remission Induction
3
2018
306
0.190
Why?
Protons
2
2020
96
0.180
Why?
Brain Stem Neoplasms
1
2023
87
0.180
Why?
Bone Neoplasms
1
2024
265
0.180
Why?
Radiometry
2
2019
56
0.170
Why?
Mitogen-Activated Protein Kinase 7
1
2021
16
0.170
Why?
Gastric Mucosa
2
2019
54
0.170
Why?
Chemotherapy, Adjuvant
2
2013
427
0.170
Why?
Cohort Studies
6
2024
6033
0.170
Why?
Survivors
2
2023
523
0.170
Why?
Transplantation, Autologous
3
2018
301
0.170
Why?
Societies, Medical
1
2026
900
0.170
Why?
Multimodal Imaging
3
2017
129
0.170
Why?
Poly(ADP-ribose) Polymerases
1
2021
88
0.170
Why?
Postoperative Complications
1
2014
2977
0.170
Why?
Radium
1
2020
4
0.170
Why?
Imaging, Three-Dimensional
1
2025
583
0.170
Why?
Breath Holding
2
2017
10
0.160
Why?
Long Term Adverse Effects
1
2020
13
0.160
Why?
Artificial Intelligence
1
2025
381
0.160
Why?
Cranial Irradiation
2
2023
85
0.160
Why?
Patient Education as Topic
1
2025
777
0.150
Why?
Stem Cell Transplantation
2
2018
189
0.150
Why?
Skin Neoplasms
2
2018
853
0.150
Why?
Plasmacytoma
1
2019
19
0.150
Why?
Cardiology
1
2022
362
0.150
Why?
Postoperative Care
2
2019
286
0.150
Why?
CD4-CD8 Ratio
1
2018
23
0.140
Why?
Radiation Dosage
1
2020
193
0.140
Why?
Mycosis Fungoides
1
2018
63
0.140
Why?
Prospective Studies
6
2026
8078
0.140
Why?
Methotrexate
2
2017
233
0.140
Why?
Electrons
1
2018
80
0.140
Why?
Breast Neoplasms, Male
1
2018
29
0.140
Why?
Glioma
1
2023
429
0.140
Why?
Area Under Curve
1
2019
332
0.140
Why?
Peritoneal Neoplasms
1
2019
104
0.130
Why?
Radiotherapy Setup Errors
1
2017
3
0.130
Why?
Platelet Count
1
2017
94
0.130
Why?
Autografts
1
2018
55
0.130
Why?
Hypothyroidism
1
2018
68
0.130
Why?
Craniospinal Irradiation
1
2017
5
0.130
Why?
Biomarkers
5
2026
4302
0.130
Why?
Dendritic Cell Sarcoma, Follicular
1
2017
4
0.130
Why?
Eye Neoplasms
1
2017
30
0.130
Why?
Leukocyte Count
1
2017
318
0.130
Why?
Osteogenesis Imperfecta
2
2007
14
0.120
Why?
Uncertainty
1
2017
146
0.120
Why?
Spinal Cord Diseases
1
2017
42
0.120
Why?
Pentostatin
1
2016
4
0.120
Why?
Neoplasm, Residual
1
2017
143
0.120
Why?
Axilla
2
2017
51
0.120
Why?
Photopheresis
1
2016
9
0.120
Why?
Methylprednisolone
1
2016
59
0.120
Why?
Predictive Value of Tests
3
2022
2123
0.120
Why?
Plasmablastic Lymphoma
1
2015
8
0.120
Why?
Confidence Intervals
1
2016
330
0.120
Why?
Collagen Type I
2
2007
143
0.120
Why?
Radiographic Image Interpretation, Computer-Assisted
1
2016
122
0.120
Why?
Caregivers
2
2025
1074
0.110
Why?
Fatal Outcome
1
2016
305
0.110
Why?
Abortion, Spontaneous
1
2016
119
0.110
Why?
Antibiotics, Antineoplastic
1
2016
140
0.110
Why?
Congenital Abnormalities
1
2016
109
0.110
Why?
Hysterectomy
2
2013
138
0.110
Why?
Anxiety
1
2023
1122
0.110
Why?
Tacrolimus
1
2016
196
0.110
Why?
Transplantation, Homologous
1
2016
419
0.110
Why?
Drug Resistance, Neoplasm
2
2019
883
0.110
Why?
Proportional Hazards Models
4
2020
1330
0.110
Why?
Blood Platelets
1
2017
379
0.100
Why?
Receptors, Progesterone
2
2014
244
0.100
Why?
Risk
1
2016
923
0.100
Why?
Age Factors
1
2021
3346
0.100
Why?
Etoposide
3
2018
168
0.100
Why?
Kidney Neoplasms
1
2018
415
0.100
Why?
Carboplatin
1
2013
164
0.090
Why?
Receptors, Estrogen
2
2014
404
0.090
Why?
Spinal Cord
1
2015
382
0.090
Why?
Anti-Inflammatory Agents
1
2016
478
0.090
Why?
Fluorouracil
1
2013
231
0.090
Why?
Lung
2
2016
4116
0.090
Why?
Pelvis
1
2013
125
0.090
Why?
Carcinoma, Non-Small-Cell Lung
1
2021
1192
0.090
Why?
Paclitaxel
1
2013
259
0.090
Why?
Immunoenzyme Techniques
1
2012
200
0.090
Why?
Neutrophils
1
2017
1127
0.090
Why?
Immunohistochemistry
1
2016
1723
0.090
Why?
Health Knowledge, Attitudes, Practice
1
2020
1420
0.090
Why?
Immunosuppressive Agents
1
2016
838
0.090
Why?
Cisplatin
1
2013
345
0.080
Why?
Triple Negative Breast Neoplasms
1
2014
218
0.080
Why?
Brain
2
2020
2969
0.080
Why?
Models, Biological
1
2018
1764
0.080
Why?
Immunotherapy
1
2015
668
0.080
Why?
Contrast Media
1
2013
497
0.080
Why?
Polymorphism, Single Nucleotide
1
2016
2181
0.070
Why?
Patient Compliance
1
2013
588
0.070
Why?
Dose-Response Relationship, Radiation
2
2020
141
0.070
Why?
Liver Neoplasms
1
2014
777
0.070
Why?
Antibodies, Monoclonal, Murine-Derived
2
2019
95
0.070
Why?
Cytarabine
2
2018
66
0.060
Why?
Biomarkers, Tumor
1
2014
1329
0.060
Why?
Integrins
1
2007
90
0.060
Why?
Nerve Growth Factor
1
2026
36
0.060
Why?
Proteoglycans
1
2007
112
0.060
Why?
Practice Guidelines as Topic
1
2014
1582
0.060
Why?
Colorectal Neoplasms
1
2014
868
0.060
Why?
Time Factors
4
2018
7134
0.060
Why?
Treatment Failure
2
2018
360
0.060
Why?
Amino Acid Substitution
1
2006
302
0.060
Why?
Brain-Derived Neurotrophic Factor
1
2026
154
0.060
Why?
Glycine
1
2006
186
0.060
Why?
Neoplasm Invasiveness
2
2017
508
0.050
Why?
Fertility Preservation
1
2025
55
0.050
Why?
Clinical Decision-Making
2
2019
364
0.050
Why?
Creatinine
1
2026
515
0.050
Why?
American Heart Association
1
2026
358
0.050
Why?
X-ray Repair Cross Complementing Protein 1
1
2023
14
0.050
Why?
Intelligence Tests
1
2023
55
0.050
Why?
Adenosine Triphosphate
1
2026
500
0.050
Why?
Standard of Care
1
2024
81
0.050
Why?
X-Rays
1
2023
27
0.050
Why?
Cell- and Tissue-Based Therapy
1
2024
78
0.050
Why?
Regression Analysis
2
2016
1001
0.050
Why?
Proto-Oncogene Proteins c-sis
1
2023
39
0.050
Why?
Analysis of Variance
2
2016
1300
0.050
Why?
Pregnancy
3
2025
7216
0.050
Why?
Inducible T-Cell Co-Stimulator Protein
1
2022
12
0.050
Why?
Phenotype
3
2021
3170
0.050
Why?
Cytidine Deaminase
1
2023
59
0.050
Why?
Terminology as Topic
1
2024
259
0.050
Why?
Brain Stem
1
2023
98
0.050
Why?
Ribose
1
2021
22
0.040
Why?
Adenosine Diphosphate
1
2021
83
0.040
Why?
Troponin T
1
2021
63
0.040
Why?
Poly (ADP-Ribose) Polymerase-1
1
2021
53
0.040
Why?
Feedback
1
2021
180
0.040
Why?
Radiosurgery
1
2024
399
0.040
Why?
Immunotherapy, Adoptive
1
2024
343
0.040
Why?
Automation
1
2020
104
0.040
Why?
Risk Management
1
2020
82
0.040
Why?
Prevalence
2
2016
2875
0.040
Why?
Incidence
2
2016
2934
0.040
Why?
Mesentery
1
2019
44
0.040
Why?
Infant
2
2025
10091
0.040
Why?
Workflow
1
2020
183
0.040
Why?
Neuropsychological Tests
1
2023
1137
0.030
Why?
Busulfan
1
2018
15
0.030
Why?
Respiration
1
2019
207
0.030
Why?
Melphalan
1
2018
43
0.030
Why?
Safety
1
2020
358
0.030
Why?
Carmustine
1
2018
52
0.030
Why?
Algorithms
1
2025
1851
0.030
Why?
Inhalation
1
2017
29
0.030
Why?
Cone-Beam Computed Tomography
1
2017
32
0.030
Why?
Breast
1
2018
156
0.030
Why?
Subacute Combined Degeneration
1
2017
1
0.030
Why?
Phosphorylation
1
2021
1708
0.030
Why?
Photons
1
2017
67
0.030
Why?
Injections, Spinal
1
2017
120
0.030
Why?
Deoxycytidine
1
2018
220
0.030
Why?
Orbit
1
2017
66
0.030
Why?
New York
1
2016
128
0.030
Why?
Time-to-Treatment
1
2019
251
0.030
Why?
Homocysteine
1
2017
152
0.030
Why?
Lymph Nodes
1
2019
509
0.030
Why?
Procarbazine
1
2015
9
0.030
Why?
Genetic Markers
1
2016
338
0.030
Why?
Observer Variation
1
2016
357
0.030
Why?
Transforming Growth Factor beta1
1
2016
177
0.030
Why?
Mutation
1
2007
4090
0.030
Why?
Folic Acid
1
2017
198
0.030
Why?
Texas
1
2016
273
0.030
Why?
Animals
2
2021
38102
0.030
Why?
Molecular Targeted Therapy
1
2018
441
0.030
Why?
Mitochondria
1
2021
993
0.030
Why?
Secondary Prevention
1
2016
251
0.030
Why?
Gastrointestinal Diseases
1
2016
222
0.030
Why?
Diagnostic Imaging
1
2017
337
0.030
Why?
Drug Administration Schedule
1
2016
782
0.030
Why?
Abortion, Induced
1
2016
112
0.030
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2017
297
0.030
Why?
Acute Disease
1
2016
1036
0.020
Why?
Pregnancy Outcome
1
2017
504
0.020
Why?
Postpartum Period
1
2016
373
0.020
Why?
Multivariate Analysis
1
2016
1547
0.020
Why?
CD8-Positive T-Lymphocytes
1
2018
923
0.020
Why?
Diagnosis, Differential
1
2017
1512
0.020
Why?
Mastectomy
1
2014
185
0.020
Why?
Ultrasonography
1
2016
788
0.020
Why?
CD4-Positive T-Lymphocytes
1
2018
1146
0.020
Why?
Surveys and Questionnaires
1
2025
6085
0.020
Why?
Ovariectomy
1
2012
166
0.020
Why?
Medical Oncology
1
2014
340
0.020
Why?
Comorbidity
1
2016
1662
0.020
Why?
Severity of Illness Index
1
2019
2933
0.020
Why?
Diet
1
2017
1278
0.020
Why?
Kidney
1
2017
1497
0.020
Why?
Quality of Life
1
2021
3211
0.020
Why?
Reproducibility of Results
1
2016
3418
0.020
Why?
Electronic Health Records
1
2017
1202
0.020
Why?
Anti-Bacterial Agents
1
2019
1925
0.020
Why?
Genetic Predisposition to Disease
1
2016
2399
0.020
Why?
Electrophoresis
1
2006
31
0.020
Why?
Case-Control Studies
1
2014
3634
0.010
Why?
DNA Mutational Analysis
1
2007
410
0.010
Why?
Databases, Genetic
1
2007
238
0.010
Why?
Protein Structure, Tertiary
1
2007
855
0.010
Why?
Collagen
1
2007
457
0.010
Why?
Mice
1
2021
18356
0.010
Why?
Binding Sites
1
2007
1311
0.010
Why?
Protein Binding
1
2007
2240
0.010
Why?
Cells, Cultured
1
2006
4151
0.010
Why?
Milgrom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)